Is BriaCell Therapeutics (BCT) halal?
BriaCell Therapeutics (TSX: BCT), the immuno-oncology biotech advancing Bria-IMT through a pivotal Phase 3 trial in metastatic breast cancer, gets a FAIL: it is pre-revenue with nil sales, so its separately disclosed financial income of C$430,205 (nine months ended April 30, 2026) is effectively 100% of income - far above the ~5% non-compliant income ceiling. Debt is zero and the business gate passes.
The two-gate Shariah screen
Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).
Gate one: the business — PASSED
BriaCell Therapeutics Corp. (TSX: BCT; NASDAQ: BCTX) is a clinical-stage biotechnology company headquartered in West Vancouver, focused on developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy in a pivotal Phase 3 trial for metastatic breast cancer; it also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer, and a soluble CD80 protein therapeutic licensed from the University of Maryland, Baltimore County. No non-permissible segments are disclosed anywhere in the filings reviewed - no alcohol, cannabis, gambling, conventional banking or insurance, weapons, pork, tobacco, or adult-entertainment activities. Developing cancer immunotherapies is not a flagged activity under standard AAOIFI-style screens. The business gate passes. Facts only, no fatwa.
Gate two: the ratios — FAILED
The non-compliant income gate fails. The Q3 FY2026 statements (nine months ended April 30, 2026) disclose a separate "Financial income, net" line: C$430,205 for the nine-month period, up from C$69,310 a year earlier - the company's FY2025 10-K describes this line as driven mainly by interest income on cash balances. The company reports nil revenue - it is pre-revenue, with no approved product - so this financial income is effectively the company's only income, i.e. interest-type income is about 100% of income, far above the ~5% ceiling. The income is earned on the company's cash pile: cash and marketable securities of about C$22.80M at April 30, 2026, strengthened by ~C$27.9M in net equity financing proceeds during the period. The debt gate passes with room to spare: total debt of C$0.00 at April 30, 2026 - liabilities are only trade payables and accruals of about C$3.7M - a debt-to-market-cap ratio of about 0% against a market capitalization of about C$49.85M (September 2026; ~8.70M shares outstanding). All figures recomputed from the cited sources; BriaCell reports in Canadian dollars.
What other screeners say
No public Zoya, Musaffa or ShariaPortfolio coverage was found for BriaCell Therapeutics (BCT/BCTX) as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.
The bottom line
BriaCell Therapeutics (BCT) is a FAIL under this site's AAOIFI-style screening: the non-compliant income gate fails because the pre-revenue biotech's separately disclosed financial income - C$430,205 in the nine months ended April 30, 2026 (mainly interest on cash balances) - is effectively 100% of income with nil revenue, far above the ~5% ceiling, earned on its ~C$22.80M cash and marketable securities pile. The debt gate passes: zero debt is about 0% of a ~C$49.85M market cap. The business gate passes: Bria-IMT is a cell-based immunotherapy in pivotal Phase 3 for metastatic breast cancer, alongside Bria-OTS and soluble CD80 programs - no haram segments are disclosed. No public Zoya, Musaffa or ShariaPortfolio rating was found for this ticker as of October 2026. As with every screener here, this is a rules-based screening of published figures, not a religious ruling - consult a qualified scholar for personal guidance.
Sources
- BriaCell Q3 FY2026 10-Q (nine months ended April 30, 2026: financial income C$430,205, nil revenue; StockTitan)
- BriaCell Form 10-Q April 30, 2026 filing (SEDAR+)
- BriaCell FY2025 10-K summary: finance income driven by interest income (TradingView)
- BriaCell financial position: C$22.80M cash and marketable securities, C$0.00 debt (TipRanks)
- BCT.TO market cap and price, September 2026 (finnhub)
- BriaCell quarterly financials: nil sales, liabilities ~C$3.7M (Barchart)
Frequently asked questions
Is BriaCell Therapeutics stock halal?
Based on this screener's AAOIFI-style checks, BriaCell fails: the pre-revenue immuno-oncology biotech's separately disclosed financial income - C$430,205 in the nine months ended April 30, 2026 - is effectively 100% of its income with nil revenue, far above the ~5% non-compliant income ceiling. Debt is zero and the business gate passes, but the income gate fails. This is a screening result, not investment advice or a religious ruling.
How does BriaCell Therapeutics score on the debt ratio?
The debt gate passes with room to spare: the company carries zero debt (C$0.00 total debt at April 30, 2026), with total liabilities of only about C$3.7M in trade payables and accruals. Against a market capitalization of about C$49.85M (September 2026), the debt-to-market-cap ratio is about 0%.
Why does a pre-revenue biotech fail the income gate?
BriaCell reports no revenue at all - it is pre-revenue, developing cancer immunotherapies (Bria-IMT pivotal Phase 3 in metastatic breast cancer, Bria-OTS, soluble CD80). Its separately disclosed financial-income line (C$430,205 for the nine months ended April 30, 2026, vs C$69,310 a year earlier - largely interest on cash balances) is therefore the company's only income. Interest-type income is effectively 100% of income, far above the ~5% ceiling, so the non-compliant income gate fails. The company holds about C$22.80M in cash and marketable securities, and that cash pile is what generates the income.
Does BriaCell Therapeutics have any haram business segments?
No: BriaCell is a clinical-stage biotechnology company developing targeted immunotherapies for cancer - Bria-IMT (cell-based immunotherapy in pivotal Phase 3 for metastatic breast cancer), Bria-OTS (personalized off-the-shelf immunotherapy for breast and prostate cancer), and a soluble CD80 protein therapeutic licensed from the University of Maryland. No alcohol, cannabis, gambling, conventional banking or insurance, weapons, pork, tobacco, or adult-entertainment activities are disclosed, so the business gate passes.
Do Zoya, Musaffa, or ShariaPortfolio rate BriaCell Therapeutics?
No public coverage was found as of October 2026: no public Zoya page is indexed for the ticker, site-scoped Musaffa searches returned nothing, and ShariaPortfolio publishes no public per-stock screening pages for it. The FAIL recorded here rests on the company's own disclosures.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).